North Andover, Massachusetts, USA (February 1, 2013) – During the recent Meeting of the Board of Directors of Bach Pharma, Inc., Chairman of the Board Dr. Steven L. Stroup announced the appointment of Mr. Daniel Cato of Durham, North Carolina to the position of President of Bach Pharma, Inc. Mr. Cato has served as a Director of Bach Pharma for the past year in addition to serving the position of Vice President of International Regulatory Affairs.
Mr. Cato is a Director and the Vice President of Project Operations for Cato Research Ltd. headquartered in Durham, North Carolina. Mr. Cato is also the Managing Director for Cato Research Washington located in Rockville, Maryland, where he is in close contact with the FDA and other Federal US agencies. Dan is also on the Board of Directors of Cato Holding Company, Ltd, located in Durham, North Carolina. In addition, he is a Director and the Secretary/Treasurer of the RTP Federal Credit Union in North Carolina, with over 12,000 members and $104 million in assets.
Dan received his BS and MS in electrical engineering from North Carolina State University, and continued on to receive his MBA with an emphasis in health care from Duke University, Fuqua School of Business Global Executive Program, the world's first global MBA program for senior executives. Dan brings with him over 20 years of experience in corporate management and pharmaceutical clinical trial management and research.
Bach Pharma CEO, Mr. Mark O. Henry, said, "Dan will undoubtedly continue to be a tremendous help to Bach Pharma. His experience in the area of regulatory affairs and clinical trials combined with his overall management experience will greatly add to Bach's management team."
About Bach Pharma
Bach Pharma, Inc., based in North Andover, MA is a pharmaceutical company engaged in the discovery, development, and commercialization of new therapeutics for the treatment of life threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia Bi-Lateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum promotes and facilitates broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint research activities related to disease control, treatment and prevention, clinical and translational research, regulatory science, and the development of new health technologies.
Incorporated in 2001, Bach developed the proprietary manufacturing technologies for its proven phthalazinedione drug platform, and owns all of the intellectual property that encompasses this entire class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of phthalazinediones. Bach maintains one of the world's most active monosodium luminol research programs focused on specific compound platforms and their derivates.
Bach is an enthusiastic member of the MassBio Council, Advancing Massachusetts Biotechnology for worldwide medical benefits, and a proud host company of the Massachusetts Life Sciences Center Internship Challenge Program.
About Cato Research Ltd
Cato Research is a contract research organization (CRO) providing a complete range of services specializing in innovative development strategies for pharmaceutical and biotechnology companies through all stages of the clinical development process. Cato Research has strategic offices through-out the world, including Tel Aviv, Israel, Fourways, South Africa, and Quebec, Canada. Cato Research is a strategic alliance partner and CRO for Bach Pharma with offices located in the Bay Colony Corporate Center in Waltham, Massachusetts.
For more information about Cato Research companies please visit their main website www.cato.com, contact them by telephone 919.361.CATO (2286), or email [email protected]
For additional information about Bach Pharma please visit their website at www.bachpharma.com, contact them by telephone 978.794.5510, or email [email protected]
For information about this press release please contact Dr. Norman Spencer at: [email protected]
Enthusiastic member of MBC - Advancing Massachusetts Biotechnology for worldwide medical benefits
Proud Intern Challenge Host Company of MLSC
Honored Member of USRCCNE - Developing mutual business and cultural opportunities for a regional network of US and Russian chambers of commerce
Planning partner for the creation of the US-Russia Scientific Exchange Forum (A Foundation for the National Institutes of Health (FNIH) Partner)